Streetbeat News

Analyst Ratings

GLPG

B of A Securities analyst Jason Gerberry maintains a Neutral rating on Galapagos (NASDAQ:GLPG) and increases the price target from $41 to $44.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:03 pm

KNSA

Wedbush analyst David Nierengarten has maintained an Outperform rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) and increased the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:01 pm

ITCI

B of A Securities analyst Ashwani Verma has maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $74 to $82.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:01 pm

ROIV

Five financial analysts have provided varied opinions on Roivant Sciences (NASDAQ:ROIV) over the past three months, with recent ratings showing 3 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target is $14.8, with a high of $17.00 and a low of $12.00, slightly up from the previous $14.67 average. Analysts from B of A Securities, Deutsche Bank, Guggenheim, and JP Morgan have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Roivant Sciences, a biopharmaceutical company, has shown a significant revenue growth rate of 196.03% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -820.27%, ROE of -32.74%, and ROA of -14.48%.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:01 pm

ASAN

Asana (NYSE:ASAN) has been rated by 7 analysts in the past three months, with a shift towards a more bearish stance in the last 30 days. The average 12-month price target for ASAN is now $19.57, down from $20.25. Analysts from firms including Piper Sandler, Morgan Stanley, Oppenheimer, HSBC, and UBS have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Asana's financial performance shows a market cap below industry average, revenue growth of 17.72%, but lagging net margin, ROE, and ROA. The company has a conservative debt-to-equity ratio of 0.85.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

ADBE

Adobe (NASDAQ:ADBE) received mixed ratings from 15 analysts in the past three months, with an average 12-month price target of $658.33, up 5.82% from the previous target. Analysts from firms like Piper Sandler, Barclays, and Citigroup have raised their price targets, reflecting a positive outlook on Adobe's performance. Adobe's financial indicators such as revenue growth, net margin, ROE, ROA, and debt management are strong compared to industry averages.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

CFLT

Confluent Inc (NASDAQ:CFLT) has received mixed analyst ratings over the past three months, with 17 analysts offering diverse perspectives. The average 12-month price target is $26.71, a significant decrease from the previous $38.56. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. Confluent's financials show a revenue growth rate of 31.93% as of September 30, 2023, but it struggles with a net margin of -46.29%, an ROE of -11.95%, an ROA of -3.95%, and a high debt-to-equity ratio of 1.41.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

AVY

Avery Dennison (NYSE:AVY) received mixed analyst ratings over the past three months, with 3 bullish and 1 underperform rating. The 12-month price target average for AVY is $209.00, slightly down from the previous $210.00. Analysts from B of A Securities, Truist Securities, and Citigroup have provided recent evaluations, with price target adjustments reflecting their latest views on the company's performance. Avery Dennison's financials show a revenue decline of -9.44% over the past 3 months, but strong profitability with a net margin of 6.59% and ROE of 6.78%. The company's international operations contribute significantly to its sales, and it maintains a balanced debt approach with a debt-to-equity ratio of 1.61.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

AAPL

The article provides a competitor analysis of Apple (NASDAQ:AAPL) in the Technology Hardware, Storage & Peripherals industry, comparing financial metrics with its peers. Apple's P/E ratio is below the industry average, suggesting growth potential, while its P/B and P/S ratios are higher, indicating a possible overvaluation. Apple's ROE, EBITDA, and gross profit are significantly above the industry average, reflecting strong profitability. However, Apple's revenue growth is below the industry average, signaling slower sales growth.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

GDRX

GoodRx Holdings (NASDAQ:GDRX) has been the subject of diverse analyst opinions over the past three months, with 7 analysts providing ratings. The consensus over the last 30 days has shifted to a more bearish stance, with 6 indifferent and 1 somewhat bearish rating. The average 12-month price target is now $5.5, down from the previous $7.57, indicating a negative sentiment. Analysts from firms including B of A Securities, JP Morgan, Goldman Sachs, RBC Capital, Truist Securities, and Morgan Stanley have all lowered their price targets for GDRX, reflecting concerns over its market performance and financials. Despite a strong market capitalization and net margin, GoodRx Holdings has seen a revenue decline of -3.93% and has a negative ROE and ROA.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm